Market Research Logo

North America Dna Vaccine Market Forecast 2018-2026

North America Dna Vaccine Market Forecast 2018-2026

KEY FINDINGS

The North America DNA vaccine market is predicted to flourish with a CAGR of 42.35% for the forecast period of 2018-2026, generating a market share of $XX million by 2026. The US DNA vaccine market is expected to capture a major share of this market, followed by Canada.

MARKET INSIGHTS

The market is segmented according to the type of technology, applications, and DNA vaccine type. Opportunities like the chance to transform the healthcare landscape, along with the ease of storage and transport of these vaccines are profoundly shaping the market growth. The market is especially gaining popularity in the animal healthcare sector as the vaccines help in the insurance and counteractive action for many veterinary diseases. Also, the ongoing clinical trials for human DNA vaccine are considerably propelling the market ahead.

COMPETITIVE INSIGHTS

The leading companies in this market are Merck & Co, Madison Vaccines Incorporated (MVI), Glaxosmithkline Inc, Novartis Ag, Xenetic Biosciences Inc, Astellas Pharma Inc, Inovio Pharmaceuticals Inc and Vical Incorporated.


1. Research Scope
1.1. Study Goals
1.2. Scope Of The Market Study
1.3. Who Will Find This Report Useful?
1.4. Study And Forecasting Years
2. Research Methodology
2.1. Sources Of Data
2.1.1. Secondary Data
2.1.2. Primary Data
2.2. Top Down Approach
2.3. Bottom-up Approach
2.4. Data Triangulation
3. Executive Summary
3.1. Market Summary
3.2. Key Findings
4. Market Determinants
4.1. Drivers
4.1.1. Dna Vaccines Shows Great Promise In Checking The Rising Prevalence Of Disease
4.1.2. Third Generation Vaccination Is Seeing A Surge In Investment
4.1.3. Increasing Adoption Of Dna Vaccines For Animal Healthcare
4.2. Restraints
4.2.1. Lengthy Regulatory Process
4.2.2. Poor Patent Protection In Some Countries
4.3. Opportunities
4.3.1. Transforming Healthcare Landscape
4.3.2. New Developments In Biotechnologies And Nanotechnologies
4.3.3. Stable Vaccines Make It Attractive To Store And Transport
4.4. Challenges
4.4.1. Vaccines For Human Usage Still Under Clinic Trail Phase
5. Market Segmentation
5.1. Market By Type 2018-2026
5.1.1. Animal Dna Vaccine
5.1.2. Human Dna Vaccine
5.2. Market By Application 2018-2026
5.2.1. Human Disease
5.2.2. Veterinary Disease
5.3. Market By Technology 2018-2026
5.3.1. Plasmid Dna Vaccines
5.3.2. Plasmid Dna Delivery
6. Key Analytics
6.1. Porter’s Five Force Model
6.1.1. Threat Of New Entrants
6.1.2. Threats Of Substitute Product
6.1.3. Bargaining Power Of Buyer
6.1.4. Bargaining Power Of Supplier
6.1.5. Intensity Of Competitive Rivalry
6.2. Key Buying Criteria
6.2.1. Efficacy
6.2.2. Cost-effectiveness
6.2.3. Stability
6.3. Key Market Players
6.3.1. Vical Incorporated
6.3.2. Sanofi
6.3.3. Merck And Corp
6.3.4. Gsk
6.4. Opportunity Matrix
6.5. Value Chain Analysis
6.5.1. R&D
6.5.2. Manufacturing
6.5.3. Raw Materials
6.5.4. Marketing, Distribution & End User
6.6. Legal, Policy And Regulatory Framework
7. Geographical Analysis
7.1. North America
7.1.1. United States
7.1.2. Canada
8. Competitive Landscape
8.1. Strategic Initiatives
8.1.1. Acquisition
8.1.2. Partnership
8.1.3. Collaboration
8.1.4. Innovation
8.1.5. Disinvestment
8.1.6. Expansion
9. Company Profile
9.1. Market Share
9.2. Astellas Pharma Inc.
9.2.1. Overview
9.2.2. Product Portfolio
9.2.3. Scot Analysis
9.2.4. Strategic Initiative
9.3. Dendreon Corporation (Acquired By Sanpower Group)
9.3.1. Overview
9.3.2. Product Portfolio
9.3.3. Scot Analysis
9.3.4. Strategic Initiative
9.4. Eli Lilly And Company
9.4.1. Overview
9.4.2. Product Portfolio
9.4.3. Scot Analysis
9.4.4. Strategic Initiative
9.5. Eurogentec S.A
9.5.1. Overview
9.5.2. Product Portfolio
9.5.3. Scot Analysis
9.5.4. Strategic Initiative
9.6. Glaxosmithkline Inc.
9.6.1. Overview
9.6.2. Product Portfolio
9.6.3. Scot Analysis
9.6.4. Strategic Initiatives
9.7. Inovio Pharmaceuticals, Inc.
9.7.1. Overview
9.7.2. Product Portfolio
9.7.3. Scot Analysis
9.7.4. Strategic Initiative
9.8. Madison Vaccines Incorporated (Mvi)
9.8.1. Overview
9.8.2. Product Portfolio
9.8.3. Scot Analysis
9.9. Merial Limited (Acquired By Boehringer Ingelheim)
9.9.1. Overview
9.9.2. Product Portfolio
9.9.3. Scot Analysis
9.9.4. Strategic Initiative
9.10. Merck & Co.
9.10.1. Overview
9.10.2. Product Portfolio
9.10.3. Scot Analysis
9.10.4. Strategic Initiative
9.11. Novartis Ag
9.11.1. Overview
9.11.2. Product Portfolio
9.11.3. Scot Analysis
9.11.4. Strategic Initiative
9.12. Sanofi
9.12.1. Overview
9.12.2. Product Portfolio
9.12.3. Scot Analysis
9.12.4. Strategic Initiative
9.13. Vgxi
9.13.1. Overview
9.13.2. Product Portfolio
9.13.3. Scot Analysis
9.13.4. Strategic Initiatives
9.14. Vical Incorporated
9.14.1. Overview
9.14.2. Product Portfolio
9.14.3. Scot Analysis
9.14.4. Strategic Initiative
9.15. Xenetic Biosciences Inc.
9.15.1. Overview
9.15.2. Product Portfolio
9.15.3. Scot Analysis
9.15.4. Strategic Initiates
9.16. Zoetis Inc
9.16.1. Overview
9.16.2. Product Portfolio
9.16.3. Scot Analysis
9.16.4. Strategic Initiates  
Table List
Table 1 North America Dna Vaccine Market 2018-2026 ($ Million)
Table 2 Interventions And Phase Of Certain Disease/Conditions
Table 3 Approaches Being Tested To Enhance The Low Immunogenicity
Table 4 Clinical Trials Of Humans Involving Dna Vaccines
Table 5 Temperature Requirements In Preservation For Various Vaccines
Table 6 North America Dna Vaccine Market By Type 2018-2026 ($ Million)
Table 7 North America Dna Vaccine Market In Animal Dna Vaccine 2018-2026($million)
Table 8 North America Dna Vaccine Market In Human Dna Vaccine 2018-2026
Table 9 North America Dna Vaccine Market By Application 2018-2026 ($ Million)
Table 10 North America Dna Vaccine Market In Human Diseases Application 2018-2026 ($million)
Table 11 North America Dna Vaccine Market In Veterinary Application 2018-2026
Table 12 North America Dna Vaccine Market By Technology 2018-2026 ($ Million)
Table 13 North America Dna Vaccine Market In Plasmid Dna Vaccines Technology 2018-2026
Table 14 North America Dna Vaccine Market In Plasmid Dna Delivery Technology 2018-2026
Table 15 Regulations To Be Followed Before Commercialization
Figures List
Figure 1 North America Dna Vaccine Market 2018-2026 ($ Million)
Figure 2 North America Dna Vaccine Market 2018-2026 ($ Million)
Figure 3 North America Dna Vaccine Market In Veterinary Diseases 2018-2026 ($ Million)
Figure 4 Share Of Trials By Vaccine Target In 2016
Figure 5 Segment Of Clinical Trials Of Dna Vaccine By Cancer Marks In 2016
Figure 6 Clinical Trials Of Gene Therapy
Figure 7 North America Dna Vaccine Market Share By Type 2017 & 2026 (%)
Figure 8 North America Dna Vaccines Market In Animal Dna Vaccines 2018-2026 ($ Million)
Figure 9 North America Dna Vaccine Market In Human Dna Vaccines 2018-2026($ Million)
Figure 10 North America Dna Vaccine Market Share By Application 2017 & 2026 (%)
Figure 11 North America Dna Vaccines Market In Human Diseases 2018-2026 ($ Million)
Figure 12 North America Dna Vaccines Market In Veterinary Application 2018-2026 ($ Million)
Figure 13 North America Dna Vaccines Market In Plasmid Dna Vaccines Technology 2018-2026 ($ Million)
Figure 14 North America Dna Vaccines Market In Plasmid Dna Delivery Technology 2018-2026 ($ Million)
Figure 15 Value Chain Analyses For Dna Vaccine Industry
Figure 16 United States Dna Vaccine Market 2018-2026 ($ Million)
Figure 17 Canada Dna Vaccine Market 2018-2026 ($ Million)
Figure 18 Market Shares Of Top Five Companies For Dna Vaccines Market In 2017

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report